CD274 and non-small cell lung carcinoma: The advent of immune checkpoint inhibitors (ICIs), specifically of antibodies targeting the programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathways, has revolutionized treatment for non-small cell lung cancer (NSCLC)1–5.